Free Trial
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$9.03 -0.01 (-0.11%)
(As of 12/20/2024 05:51 PM ET)

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Key Stats

Today's Range
$8.92
$9.23
50-Day Range
$6.99
$10.44
52-Week Range
$4.71
$10.67
Volume
1.58 million shs
Average Volume
1.60 million shs
Market Capitalization
$1.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Moderate Buy

Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
47th Percentile Overall Score

AUPH MarketRank™: 

Aurinia Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 602nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is -60.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is -60.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.34% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 9.59%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.34% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 9.59%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • Search Interest

    Only 11 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,416.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

Insiders Are Loving These 6 Stocks Right Now
Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed
Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $8.99 at the start of the year. Since then, AUPH shares have increased by 0.4% and is now trading at $9.03.
View the best growth stocks for 2024 here
.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported $0.01 EPS for the quarter, meeting analysts' consensus estimates of $0.01. Aurinia Pharmaceuticals's quarterly revenue was up 37.6% on a year-over-year basis.

Aurinia Pharmaceuticals' top institutional shareholders include State Street Corp (2.06%), Geode Capital Management LLC (1.23%), Charles Schwab Investment Management Inc. (0.52%) and Segall Bryant & Hamill LLC (0.39%). Insiders that own company stock include Peter Greenleaf, Scott Michael Habig, Joseph M Miller, Stephen P Robertson, George M Milne Jr, David RW Jayne and Jeffrey Allen Bailey.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
8/01/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$13.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+10.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-78,020,000.00
Pretax Margin
-9.14%

Debt

Sales & Book Value

Annual Sales
$220.36 million
Book Value
$2.63 per share

Miscellaneous

Free Float
137,022,000
Market Cap
$1.29 billion
Optionable
Optionable
Beta
1.41

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners